A detailed history of Dillon & Associates Inc transactions in Astrazeneca PLC stock. As of the latest transaction made, Dillon & Associates Inc holds 32,850 shares of AZN stock, worth $2.18 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares
32,850
Previous 25,837 27.14%
Holding current value
$2.18 Million
Previous $2.02 Million 27.15%
% of portfolio
0.36%
Previous 0.29%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$76.67 - $87.62 $537,686 - $614,479
7,013 Added 27.14%
32,850 $2.56 Million
Q2 2024

Aug 06, 2024

BUY
$66.81 - $80.83 $116,917 - $141,452
1,750 Added 7.27%
25,837 $2.02 Million
Q1 2024

Apr 30, 2024

BUY
$61.03 - $69.57 $51,631 - $58,856
846 Added 3.64%
24,087 $1.64 Million
Q4 2023

Feb 08, 2024

BUY
$61.89 - $69.28 $54,772 - $61,312
885 Added 3.96%
23,241 $1.56 Million
Q3 2023

Nov 13, 2023

BUY
$64.85 - $71.7 $95,653 - $105,757
1,475 Added 7.06%
22,356 $1.52 Million
Q2 2023

Aug 08, 2023

BUY
$69.91 - $75.81 $187,918 - $203,777
2,688 Added 14.77%
20,881 $1.5 Million
Q1 2023

May 02, 2023

BUY
$63.15 - $71.6 $727,993 - $825,404
11,528 Added 172.96%
18,193 $1.26 Million
Q1 2023

May 01, 2023

SELL
$63.15 - $71.6 $611,418 - $693,231
-9,682 Reduced 59.23%
6,665 $462,000
Q4 2022

Feb 06, 2023

BUY
$54.21 - $70.44 $129,941 - $168,844
2,397 Added 17.18%
16,347 $1.11 Million
Q3 2022

Nov 08, 2022

BUY
$53.02 - $135.75 $175,125 - $448,382
3,303 Added 31.02%
13,950 $767,000
Q2 2022

Jul 26, 2022

BUY
$59.26 - $71.14 $109,216 - $131,111
1,843 Added 20.93%
10,647 $703,000
Q1 2022

May 06, 2022

BUY
$55.72 - $67.12 $119,185 - $143,569
2,139 Added 32.09%
8,804 $581,000
Q4 2021

Feb 14, 2022

BUY
$54.02 - $63.83 $360,043 - $425,426
6,665 New
6,665 $387,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $205B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Dillon & Associates Inc Portfolio

Follow Dillon & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dillon & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dillon & Associates Inc with notifications on news.